Listen, folks, trauma—it’s a big deal, a huge problem for public health, believe me. People are saying, and I’ve heard it, that our genes, they play a big role in how we handle injuries. It’s incredible. We’ve got these beta-adrenergic receptor polymorphisms, and they’re making a huge impact on how we deal with trauma. It’s all about personalized medicine, that’s the future, and it’s going to be tremendous.

Now, some people, they’re asking, “Why do some have it worse than others after an injury?” And I’ll tell you, it’s not just about the genes, although they’re very important. It’s this big, complex mix of your environment and your genes. We’ve got the best people working on this, the best, and they’re finding out why there’s so much variability.

When trauma hits, it’s like a cascade, a big one. But that’s not the whole story. We need to understand, really understand, how trauma and our genetic makeup, especially these adrenergic variations, work together. It’s all happening at the molecular level, and it’s fascinating, really.

We’ve got to find these genetic markers, these physiological markers, to help us manage trauma right from the get-go. It’s all about getting to the bedside with the right tools, the best tools. And from there, we’re going to find these biomarkers, and they’re going to be fantastic. They’ll help us spot the people who need help the most, the ones we need to jump in and help first.

This is how we’re going to bring personalized medicine to neurotrauma. It’s going to be big, really big. We’re going to make trauma care great, and we’re going to do it by understanding our genes. It’s going to be something else, folks.